OCUGEN, INC. Lease, Cost
OCUGEN, INC. (OCGN) reported Lease, Cost of $1.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-04
- OCUGEN, INC. lease, cost for the quarter ending 2022-12-31 was $265.00K, a 42.47% increase year-over-year.
- OCUGEN, INC. lease, cost for the quarter ending 2022-09-30 was $232.00K, a 152.17% increase year-over-year.
- OCUGEN, INC. lease, cost for the quarter ending 2022-06-30 was $229.00K, a 160.23% increase year-over-year.
- OCUGEN, INC. lease, cost for the quarter ending 2022-03-31 was $207.00K, a 111.22% increase year-over-year.
- OCUGEN, INC. lease, cost for fiscal 2025 was $1.86M, a 48.96% increase from fiscal 2024.
- OCUGEN, INC. lease, cost for fiscal 2024 was $1.25M, a 10.83% increase from fiscal 2023.
- OCUGEN, INC. lease, cost for fiscal 2023 was $1.13M, a 20.82% increase from fiscal 2022.
- OCUGEN, INC. lease, cost for fiscal 2022 was $932.00K, a 100.43% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $1.86M 10-K · filed 2026-03-04 | |||||||
| 2024-12-31 | $1.25M 10-K · filed 2026-03-04 | |||||||
| 2023-12-31 | $1.13M 10-K · filed 2025-03-05 | |||||||
| 2022-12-31 | $265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $497.00K derived: sum of 2 quarters · filed 2024-04-16 | $726.00K derived: sum of 3 quarters · filed 2024-04-16 | $932.00K 10-K · filed 2024-04-16 | ||||
| 2022-09-30 | $232.00K 10-Q · filed 2022-11-08 | $461.00K derived: sum of 2 quarters · filed 2022-11-08 | $667.00K 10-Q · filed 2022-11-08 | $854.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2022-06-30 | $229.00K 10-Q · filed 2022-08-05 | $435.00K 10-Q · filed 2022-08-05 | $622.00K derived: sum of 3 quarters · filed 2023-02-28 | $714.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2022-03-31 | $207.00K 10-Q · filed 2022-05-06 | $393.00K derived: sum of 2 quarters · filed 2023-02-28 | $485.00K derived: sum of 3 quarters · filed 2023-02-28 | $573.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $278.00K derived: sum of 2 quarters · filed 2023-02-28 | $366.00K derived: sum of 3 quarters · filed 2023-02-28 | $465.00K 10-K · filed 2023-02-28 | ||||
| 2021-09-30 | $92.00K 10-Q · filed 2022-11-08 | $180.00K derived: sum of 2 quarters · filed 2022-11-08 | $279.00K 10-Q · filed 2022-11-08 | $347.00K derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $88.00K 10-Q · filed 2022-08-05 | $186.00K 10-Q · filed 2022-08-05 | $255.00K derived: sum of 3 quarters · filed 2022-08-05 | $324.00K derived: sum of 4 quarters · filed 2022-08-05 | ||||
| 2021-03-31 | $98.00K 10-Q · filed 2022-05-06 | $167.00K derived: sum of 2 quarters · filed 2022-05-06 | $236.00K derived: sum of 3 quarters · filed 2022-05-06 | $304.00K derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $138.00K derived: sum of 2 quarters · filed 2022-02-28 | $206.00K derived: sum of 3 quarters · filed 2022-02-28 | $274.00K 10-K · filed 2022-02-28 | $274.21K 10-K · filed 2021-03-19 | |||
| 2020-09-30 | $69.00K 10-Q · filed 2021-11-09 | $68.86K 10-Q · filed 2020-11-06 | $137.00K derived: sum of 2 quarters · filed 2021-11-09 | $205.00K 10-Q · filed 2021-11-09 | $205.36K 10-Q · filed 2020-11-06 | $275.17K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $68.00K 10-Q · filed 2021-08-06 | $67.77K 10-Q · filed 2020-08-14 | $137.00K 10-Q · filed 2021-08-06 | $136.64K 10-Q · filed 2020-08-14 | $206.17K derived: sum of 3 quarters · filed 2022-02-28 | $275.15K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $69.00K 10-Q · filed 2021-05-07 | $68.86K 10-Q · filed 2020-05-08 | $138.17K derived: sum of 2 quarters · filed 2022-02-28 | $207.15K derived: sum of 3 quarters · filed 2022-02-28 | $309.88K derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $69.17K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $138.15K derived: sum of 2 quarters · filed 2022-02-28 | $240.88K derived: sum of 3 quarters · filed 2022-02-28 | $330.00K 10-K · filed 2022-02-28 | $330.06K 10-K · filed 2020-03-27 | |||
| 2019-09-30 | $68.98K 10-Q · filed 2020-11-06 | $171.71K derived: sum of 2 quarters · filed 2020-11-06 | $260.83K 10-Q · filed 2020-11-06 | |||||
| 2019-06-30 | $102.73K 10-Q · filed 2020-08-14 | $191.85K 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $89.12K 10-Q · filed 2020-05-08 | |||||||
| 2018-06-30 | $191.85K 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |